Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) was the target of a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 3,000 shares, a drop of 55.9% from the December 31st total of 6,800 shares. Based on an average daily trading volume, of 16,200 shares, the short-interest ratio is currently 0.2 days.
Adlai Nortye Price Performance
Adlai Nortye stock traded up $0.06 during mid-day trading on Friday, reaching $2.12. 5,049 shares of the company’s stock were exchanged, compared to its average volume of 11,537. Adlai Nortye has a twelve month low of $1.85 and a twelve month high of $17.48. The company has a fifty day moving average of $2.18 and a 200-day moving average of $2.47.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Adlai Nortye in a research report on Monday, November 11th.
About Adlai Nortye
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Featured Articles
- Five stocks we like better than Adlai Nortye
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- Quiet Period Expirations Explained
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
